The North America Actinic Keratosis Treatment Market would witness market growth of 3.7% CAGR during the forecast period (2022-2028).
Anyone who spends a significant amount of time outside without protection runs the possibility of creating one or more AKs, regardless of the weather. UV rays may penetrate through clouds, even when it is cloudy. The chance of getting AKs is increased if the immune system is compromised. Medical procedures like immunosuppressive or chemotherapy therapy might impair the immune system.
If someone has a disease like leukemia, lymphoma, or HIV, the immune system may also be compromised. The immune system is suppressed by prolonged UV exposure, which lowers its capacity to repair more damage. Although anybody can get AKs, those with fair skin are more likely to do so, especially those with blond or red hair, green or blue eyes, or skin that gets freckles or burns readily.
Because UV harm to the skin builds up over time, the total lifetime impact increases with age. This explains the prevalence of AKs in individuals over the age of 40. There is a growing use of self-administered therapy and the accessibility of options for home-based therapy. Actinic keratosis is typically treated topically using topical creams containing fluorouracil, a chemotherapy agent, as well as other medications including Imiquimod (INN) gels and diclofenac, an analgesic.
With the simple availability of improved treatments in North America, including combination therapy and monotherapy, actinic keratosis is becoming more common and there is a rising need for minimally invasive procedures. The increasing cancer research initiatives in North America are also anticipated to increase the requirement for actinic keratosis treatments. This is because these treatments are essential for preventing the growth of cancer tumors and easing the burden that rising cancer incidence has on the healthcare system.
The US market dominated the North America Actinic Keratosis Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,190.5 Million by 2028.The Canada market is poised to grow at a CAGR of 6.1% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 5.2% during (2022 - 2028).
Based on Drug Class, the market is segmented into Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers and Others. Based on Therapy, the market is segmented into Surgery, Topical and Photodynamic Therapy. Based on End-use, the market is segmented into Hospitals, Private Clinics, Homecare and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Actinic Keratosis Treatment Market is Estimated to reach $8 Billion by 2028, at a CAGR of 4.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Almirall, S.A, LEO Pharma A/S, Biofrontera AG, Sun Pharmaceuticals Industries Ltd., 3M Company, Bausch Health Companies, Inc., Novartis AG, Viatris, Inc., and Galderma S.A.
By Drug Class
By Therapy
By End-use
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
